In BRAFV600E-mutated colorectal cancers, CEMIP expression is increased in a β-catenin-dependent manner, which contributes to acquired resistance to Mitogen-activated protein kinase kinase 1 (MEK1) inhibition [47]. The gene discussed is MAP2K1; the disease is colorectal cancer.